Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.64 |
| ▸ | PI4KA | P42356 | 3/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.58 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906617 | 0.98 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL67131 | 0.94 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL5033136 | 0.87 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL11012652 | 0.86 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL21469779 | 0.86 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL23228230 | 0.86 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL11010323 | 0.86 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL1741560 | 0.86 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL16057701 | 0.86 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADCY5PI4KA | |
| SCHEMBL8467390 | 0.86 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BADCY5PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1908 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419665-B1 | TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-10-30 | — | — | EP | claimed |
| US-8288354-B2 | Natural antisense and non-coding RNA transcripts as drug targets | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-10-16 | — | — | US | claimed |
| JP-3471025-B2 | — | — | 2003-11-25 | — | — | JP | claimed |
| US-20030194738-A1 | Antisense oligonucleotide compositions and methods for the modulation of activating protein 1 | DEAN NICHOLAS M (US) | 2003-10-16 | — | — | US | claimed |
| US-20020039741-A1 | Antitumor agent | DEAN NICHOLAS M (US) | 2002-04-04 | — | — | US | claimed |
| EP-0957926-A4 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS INC (US) | 2002-01-23 | — | — | EP | claimed |
| US-6319906-B1 | FOR THERAPY OF AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE, FOR INHIBITING ALLOGRAFT REJECTION | ISIS PHARMACEUTICALS | 2001-11-20 | — | — | US | claimed |
| US-6312900-B1 | FOR MODULATING METASTASIS OF MALIGNANT TUMORS VIA MODULATION OF ACTIVATING PROTEIN 1 | ISIS PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | claimed |
| JP-2000507833-A | — | — | 2000-06-27 | — | — | JP | claimed |
| EP-0957926-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1998029124-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| EP-4746853-A1 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-12637682-B2 | Protein translational control | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2026-05-26 | — | — | US | disclosed |
| US-12637674-B2 | Inhibition of lncExACT1 to treat heart disease | THE GENERAL HOSPITAL CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-12618071-B2 | Multimeric oligonucleotides with divided strands | MPEG LA, L.L.C. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-1998029124-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| EP-0095089-B1 | IMPROVED HOMOGENEOUS BINDING ASSAY METHOD AND REAGENT SYSTEM, TEST KIT AND TEST DEVICE THEREFOR | MILES LABORATORIES, INC. (US) | 1986-03-05 | — | — | EP | disclosed |
| EP-0095089-A1 | Improved homogeneous binding assay method and reagent system, test kit and test device therefor | MILES LABORATORIES, INC. (US) | 1983-11-30 | — | — | EP | disclosed |
| EP-0027631-B1 | FLAVIN ADENINE DINUCLEOTIDE-LABELED PROTEIN AND POLYPEPTIDE CONJUGATES | MILES LABORATORIES, INC. (US) | 1982-05-05 | — | — | EP | disclosed |
| EP-0027631-A1 | Flavin adenine dinucleotide-labeled protein and polypeptide conjugates | MILES LABORATORIES, INC. (US) | 1981-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637682-B2 | Protein translational control | RNGTT, RNMT, METTL16 | ADORA2A 3361/4885ADORA1 4211/4885ADORA2B 2903/4885 |
| US-12637674-B2 | Inhibition of lncExACT1 to treat heart disease | DACH1, TNNT2, CDH1 | ADORA2A 1896/4885ADORA1 1684/4885ADORA2B 2126/4885 |
| US-12618071-B2 | Multimeric oligonucleotides with divided strands | DCLRE1B, MICA, LIG1 | ADORA2A 3002/4885ADORA1 2754/4885ADORA2B 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.